Biologics
PharmaEssentia Corp.
Products
BESREMI (Ropeginterferon alfa-2b)
BESREMi is the FDA-approved treatment indicated for adults with polycythemia vera (PV) that targets the source of the disease.
Interests
- In-Licensing
Contact Information
- NameHarvey Chin
- PositionHead of Global Strategy
- Emailharvey_chin@pharmaessentia.com
- https://www.pharmaessentia.com/